1. Generics Bulletin
  2. >>Business

SPC Waiver Builds Momentum After EU Vote

 
• By Dave Wallace

Several EU-level endorsements for a proposed SPC manufacturing waiver – which would allow manufacturing within Europe during the SPC period for export, as well as stockpiling for ‘day one’ launch upon SPC expiry – have been applauded by the region’s off-patent industry. However, originators are doubling down on lobbying efforts against such changes.

EU parliament
Parliament endorses SPC waiver • Source: Shutterstock

A vote by the European Parliament’s international trade committee, INTA, endorsing a proposed waiver allowing manufacturing during the term of supplementary protection certificates (SPCs) has been applauded by off-patent industry association Medicines for Europe. It follows recognition by the EU’s competitiveness council as well as “constructive amendments” to the current SPC waiver proposal that were recently offered by the Parliament’s health committee.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By Dean Rudge

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.